Abstract
1. Stop injection/infusion immediately
2. Get extravasation kit
3. Put on (sterile) gloves
4. Replace infusion lead or syringe with 5 ml disposable syringe and aspirate slowly as much as possible of the extravasated drug; Cave! do not exert pressure on extravasation area
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Original articles
Moore GE, DiPaolo JA, Kondo T: The chemotherapeutic effects and complications of actinomycin D in patients with advanced cancer. Cancer 11: 1204–1214, 1958.
Larson DL: What is the appropriate management of tissue -extravasation by antitumor agents? Plast Reconstr Surg 75: 397–402, 1985.
Buchanan GR, Buchsbaum HJ, O’Banion K, et al: Extravasation of dactinomycin, vincristine, and cisplatin: studies in an animal model. Med Pediatr Oncol 13: 375–380, 1985.
Secondary literature
Ignoffo RJ, Friedman MA: Therapy of local toxicities caused by extravasation of cancer chemotherapeutic drugs. Cancer Treat Rev 7: 17–27, 1980.
Schneider G: Paravasate von Zytostatika. Diagnostik und -Therapie. Aina S. Schneider Verlag, 6th edition: 1–17, 1999.
Krämer J, Stützle M: Zytostatika-Paravasation – Wie ist vorzugehen? Krankenhauspharmazie 23: 261–268, 2002.
Dorr RT: Pharmacologic management of vesicant chemotherapy extravasations. In: Dorr RT, Von Hoff DD (eds) Cancer -Chemotherapy Handbook. Appleton & Lange, 2nd edition: 109–118, 1994.
Stanley A: Managing complications of chemotherapy administration. In: Allwood M, Stanley A, Wright P (eds) The Cytotoxics Handbook. Radcliffe Medical Press, 4th edition: 119–193, 2002.
Gain M, Melzer S, Meyer-Jürshof A, et al: Allgemeiner Teil: -Behandlung von Paravasaten. In: Gain M, et al (eds) ADKA–Zytostatika-Handbuch, Pharmazeutisch-wissenschaftliche Monographien. Verlag Heiner Biller, vol 1, 2nd edition: A42–44, 1997.
Bertelli G: Prevention and management of extravasation of cytotoxic drugs. Drug Safety 12: 245–255, 1995.
Frei E: The clinical use of actinomycin. Cancer Chemother Rep 58: 49–54, 1974.
Mullin S, Beckwith MC, Tyler LS: Prevention and management of antineoplastic extravasation injury. Hosp Pharm 35: 57–76, 2000.
Dorr RT: Antidotes to vesicant chemotherapy extravasations. Blood Rev 4: 41–60, 1990.
Schneider SM, Distelhorst CW: Chemotherapy-induced emergencies. Semin Oncol 16: 572–578, 1989.
Barth J: Paravasate und deren Behandlung. In: Barth J (ed) -Zytostatika-Herstellung in der Apotheke. Deutscher Apotheker Verlag, chapter. VI-3: 1–9, 2000.
Summary of product characteristics Lyovac-Cosmegen® (-Germany), MSD Sharp & Dohme, April 2003.
Jordan K, Grothe W, Schmoll HJ: Paravasation von Zytostatika: Prävention und Therapie. Dtsch Med Wochenschr 130: 33–37, 2005.
Fenchel K, Karthaus M: Zytostatika-Paravasate – gibt es neue Empfehlungen zum therapeutischen Vorgehen? Wien Med Wochenschr 151: 44–46, 2001.
Ener RA, Meglathery SB, Styler M: Extravasation of systemic hemato-oncological therapies. Ann Oncol 15: 858–862, 2004.
Koppel RA, Boh EE: Cutaneous reactions to chemotherapeutic agents. Am J Med Sci 321: 327–335, 2001.
Alley E, Green R, Schuchter L: Cutaneous toxicities of cancer therapy. Curr Opin Oncol 14: 212–216, 2002.
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2010 Springer-Verlag/Wien
About this chapter
Cite this chapter
Mader, I., Fürst-Weger, P., Mader, R., Nogler-Semenitz, E., Wassertheurer, S. (2010). Dactinomycin. In: Extravasation of Cytotoxic Agents. Springer, Vienna. https://doi.org/10.1007/978-3-211-88893-3_25
Download citation
DOI: https://doi.org/10.1007/978-3-211-88893-3_25
Publisher Name: Springer, Vienna
Print ISBN: 978-3-211-88889-6
Online ISBN: 978-3-211-88893-3
eBook Packages: MedicineMedicine (R0)